Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.

[1]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[2]  M. Ducreux,et al.  Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Fukuoka,et al.  Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Taron,et al.  Cytotoxic Effects of Topotecan Combined with Various Active G2/M-Phase Anticancer Drugs in Human Tumor-Derived Cell Lines , 2000, Investigational New Drugs.

[5]  J. Sloan,et al.  Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Hainsworth,et al.  Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Nakanishi,et al.  Effect of CPT-11 in combination with other anticancer agents in lung cancer cells , 1997, Anti-cancer drugs.

[8]  R. James,et al.  Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Kohn,et al.  Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. , 1996, Cancer research.

[10]  L. Grochow,et al.  Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. , 1996, Journal of the National Cancer Institute.

[11]  B. Burchell,et al.  Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.

[12]  E. Eisenhauer.  Docetaxel: current status and future prospects. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Oosterom,et al.  Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. , 1995 .

[14]  R. Motzer,et al.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.

[15]  M. Fukuoka,et al.  CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Hérait,et al.  Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.